Yahoo Finance

H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of approximately $935M reflects about a 72% premium to the closing price on March 4, the analyst noted.

Discover the Best Stocks and Maximize Your Portfolio:

• See what stocks are receiving Strong Buy ratings from top-rated analysts.

• Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CMRX:

• Chimerix downgraded to Neutral from Outperform at Wedbush

• Chimerix Merges with Jazz Pharmaceuticals in $935M Deal

• Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash

• Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M

• Chimerix’s Strategic Pause and Financial Strength Bolster Long-term Buy Rating Amid Regulatory Milestones